Author Affiliations: University of British Columbia James Hogg Research Centre and the Institute for Heart and Lung Health, St Paul's Hospital, Vancouver, British Columbia, Canada (Drs Sin and Park); Division of Respiratory Medicine, Department of Medicine, University of British Columbia (Dr Sin); and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Seoul, South Korea (Dr Park).
Chronic obstructive pulmonary disease (COPD) is a common, progressive lung condition, characterized by cough and dyspnea and punctuated by episodes of acute exacerbations or “lung attacks” during which these symptoms significantly increase. These lung attacks can induce severe symptoms, causing patients to seek urgent medical care and can result in respiratory failure and death. In the United States, COPD exacerbations are responsible for more than 800 000 hospital admissions each year and 143 000 deaths annually, making it the third leading cause of mortality.1 Furthermore, acute exacerbations accelerate decline in lung function, reduce patients' quality of life, and increase health care use (with exacerbation management accounting for up to 70% of the total direct costs of COPD management).2
Sin DD, Park HY. Steroids for Treatment of COPD Exacerbations: Less Is Clearly More. JAMA. 2013;309(21):2272–2273. doi:10.1001/jama.2013.5644
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.